Wordt geladen...
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
BACKGROUND: The CD133 antigen is a marker of radio- and chemo-resistant stem cell populations in glioblastoma (GBM). The O(6)-methylguanine DNA methyltransferase (MGMT) enzyme is related with temozolomide (TMZ) resistance. Our propose is to analyze the prognostic significance of the CD133 antigen an...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2012
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3551841/ https://ncbi.nlm.nih.gov/pubmed/23245659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-10-250 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|